A study of PA DNA/dendron nanoparticles for genetic immunisation against anthrax

Open Vaccine Journal

Volumn 3, Issue 1, 2010, Pages 38-44

  Ribeiro, Suzie J ^a   Rijpkema, Sjoerd G ^b   Durrani, Zarmina ^b   Florence, A T ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Dendriplexes; Dendron; DNA vaccines; Nanoparticle; Protective antigen

Indexed keywords

ANTHRAX TOXIN; BACTERIAL ANTIGEN; DNA VACCINE; NANOPARTICLE; POLYLYSINE; PROTECTIVE ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DNA IMMUNIZATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SYNTHESIS; FEMALE; IMMUNOGENICITY; IN VITRO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; VACCINE PRODUCTION;

EID: 79953861695     PISSN: None     EISSN: 18750354     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Ivins, B.E.; Welkos, S.L. Cloning and expression of the Bacillus anthracis protective antigen gene in Bacillus subtilis. Infect. Immun., 1986, 54 (2), 537-542.
2. Leppla, S.H.; Robbins, J.B.; Schneerson, R.; Shiloach, J. Development of an improved vaccine for anthrax. J Clin. Invest., 2002, 110 (2), 141-144.
3. Turnbull, P.C. Anthrax vaccines: past, present and future. Vaccine, 1991, 9 (8), 533-539.
4. Whiting, G.C.; Rijpkema, S.; Adams, T.; Corbel, M.J. Characterisation of adsorbed anthrax vaccine by two-dimensional gel electrophoresis. Vaccine, 2004, 22 (31-32), 4245-4251.
5. Casadevall, A. Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg. Infect. Dis., 2002, 8 (8), 833-841.
6. Pitt, M.L.; Little, S.F.; Ivins, B.E.; Fellows, P.; Barth, J.; Hewetson, J.; Gibbs, P.; Dertzbaugh, M.; Friedlander, A.M. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine, 2001, 19 (32), 4768-4773.
7. Little, S.F.; Ivins, B.E.; Fellows, P.F.; Friedlander, A.M. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect. Immun., 1997, 65, 5171-5175.
8. Brey, R.N. Molecular basis for improved anthrax vaccines. Adv. Drug Deliv. Rev., 2005, 57 (9), 1266-1292.
9. Hermanson, G.; Whitlow, V.; Parker, S.; Tonsky, K.; Rusalov, D.; Ferrari, M.; Lalor, P.; Komai, M.; Mere, R.; Bell, M.; Brenneman, K.; Mateczun, A.; Evans, T.; Kaslow, D.; Galloway, D.; Hobart, P. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc. Natl. Acad. Sci. USA, 2004, 101 (37), 13601-13606.
10. Mollenkopf, H.J.; Dietrich, G.; Fensterle, J.; Grode, L.; Diehl, K.D.; Knapp, B.; Singh, M.; O'Hagan, D.T.; Ulmer, J.B.; Kaufmann, S.H. Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles. Vaccine, 2004, 22 (21-22), 2690-2695.
11. Xie, H.; Gursel, I.; Ivins, B.E.; Singh, M.; O'Hagan, D.T.; Ulmer, J. B.; Klinman, D.M. CpG Oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infect. Immun., 2005, 73 (2), 828-833.
12. Ribeiro, S.J.; Rijpkema, S.G.; Durrani, Z.; Florence, A.T. PLGAdendrons enhance immunogenicity of a DNA vaccine against anthrax in mice. Int. J. Pharm., 2007, 331 (2), 228-232.
13. Svenson, S.; Tomalia, D.A. Dendrimers in biomedical applications--reflections on the field. Adv. Drug Deliv. Rev., 2005, 57, 2106-2129.
14. Boas, U.; Heegaard, P.M. Dendrimers in drug research. Chem. Soc. Rev., 2004, 33 (1), 43.
15. Golan, R.; Pietrasanta, L.I.; Hsieh, W.; Hansma, H.G. DNA toroids: stages in condensation. Biochemistry, 1999, 38 (42), 14069-14076.
16. Lee, C.G.; Choi, S.Y.; Park, S.H.; Park, K.S.; Ryu, S.H.; Sung, Y.C. The synthetic peptide Trp-Lys-Tyr-Met-Val-D-Met as a novel adjuvant for DNA vaccine. Vaccine, 2005, 23 (38), 4703-4710.
17. Dasgupta, S.; Bhinge, A.; Chandran, V.; Sewlikar, S.; Nimbkar, A.; Datta, D. Role of L-lysine HCl in immunopotentiation towards development of suitable tuberculosis vaccination. Vaccine, 2003, 21 (32), 4722-4727.
18. Hahn, U.K.; Alex, M.; Czerny, C.P.; Bohm, R.; Beyer, W. Protection of mice against challenge with Bacillus anthracis STI spores after DNA vaccination. Int. J. Med. Microbiol., 2004, 294 (1), 35-44.
19. Sakthivel, T.; Toth, I.; Florence, A.T. Synthesis and physicochemical properties of lipophilic polyamide dendrimers. Pharm. Res., 1998, 15, 776-782.
20. Hering, D.; Thompson, W.; Hewetson, J.; Little, S.; Norris, S.; Pace-Templeton, J. Validation of the anthrax lethal toxin neutralization assay. Biologicals, 2004, 32 (1), 17-27.
21. Williamson, E.D.; Bennett, A.M.; Perkins, S.D.; Beedham, R.J.; Miller, J.; Baillie, L.W. Co-immunisation with a plasmid DNA cocktail primes mice against anthrax and plague. Vaccine, 2002, 20 (23-24), 2933-2941.
22. Welkos, S.L.; Friedlander, A.M. Pathogenesis and genetic control of resistance to the Sterne strain of Bacillus anthracis. Microb. Pathog., 1988, 4 (1), 53-69.
23. Galloway, D.R.; Baillie, L. DNA vaccines against anthrax. Expert. Opin. Biol. Ther., 2004, 4 (10), 1661-1667.
24. Flick-Smith, H.C.; Waters, E.L.; Walker, N.J.; Miller, J.; Stagg, A. J.; Green, M.; Williamson, E.D. Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain. Microb. Pathog., 2005, 38 (1), 33-40.
25. Gu, M.L.; Leppla, S.H.; Klinman, D.M. Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen. Vaccine, 1999, 17 (4), 340-344.
26. Hahn, U.K.; Boehm, R.; Beyer, W. DNA vaccination against anthrax in mice-combination of anti-spore and anti-toxin components. Vaccine, 2006, 24 (21), 4569-4571.
27. Hahn, U.K.; Aichler, M.; Boehm, R.; Beyer, W. Comparison of the immunological memory after DNA vaccination and protein vaccination against anthrax in sheep. Vaccine, 2006, 24 (21), 4595-4597.
28. Boyaka, P.N.; Tafaro, A.; Fischer, R.; Leppla, S.H.; Fujihashi, K.; McGhee, J.R. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J. Immunol., 2003, 170 (11), 5636-5643.
29. Ivins, B.E.; Pitt, M.L.; Fellows, P.F.; Farchaus, J.W.; Benner, G.E.; Waag, D.M.; Little, S.F.; Anderson-GW, J.; Gibbs, P.H.; Friedlander, A.M. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine, 1998, 16 (11-12), 1141-1148.
30. Klinman, D.M.; Xie, H.; Little, S.F.; Currie, D.; Ivins, B.E. CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. Vaccine, 2004, 22 (21-22), 2881-2886.